Logo image of AERI

AERIE PHARMACEUTICALS INC (AERI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AERI - US00771V1089 - Common Stock

15.25 USD
+0.01 (+0.07%)
Last: 11/18/2022, 8:21:01 PM
15.25 USD
0 (0%)
After Hours: 11/18/2022, 8:21:01 PM
Fundamental Rating

2

AERI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. AERI has a bad profitability rating. Also its financial health evaluation is rather negative. AERI is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • AERI had negative earnings in the past year.
  • In the past year AERI had a positive cash flow from operations.
AERI Yearly Net Income VS EBIT VS OCF VS FCFAERI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -50M -100M -150M -200M

1.2 Ratios

Industry RankSector Rank
ROA -9.73%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AERI Yearly ROA, ROE, ROICAERI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 200 -200 400 -400 -600

1.3 Margins

Industry RankSector Rank
OM -12.49%
PM (TTM) -17.09%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AERI Yearly Profit, Operating, Gross MarginsAERI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -200 -400 -600 -800

More info and screens

2

2. Health

2.1 Basic Checks

  • AERI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AERI has more shares outstanding
  • Compared to 1 year ago, AERI has a worse debt to assets ratio.
AERI Yearly Shares OutstandingAERI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
AERI Yearly Total Debt VS Total AssetsAERI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

2.2 Solvency

  • AERI has an Altman-Z score of -2.71. This is a bad value and indicates that AERI is not financially healthy and even has some risk of bankruptcy.
  • The Debt to FCF ratio of AERI is 118.54, which is on the high side as it means it would take AERI, 118.54 years of fcf income to pay off all of its debts.
  • AERI has a Debt/Equity ratio of -1.91. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity -1.91
Debt/FCF 118.54
Altman-Z -2.71
ROIC/WACCN/A
WACC8.3%
AERI Yearly LT Debt VS Equity VS FCFAERI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 100M -100M 200M

2.3 Liquidity

  • AERI has a Current Ratio of 2.27. This indicates that AERI is financially healthy and has no problem in meeting its short term obligations.
  • AERI has a Quick Ratio of 1.92. This is a normal value and indicates that AERI is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 1.92
AERI Yearly Current Assets VS Current LiabilitesAERI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

  • AERI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.48%, which is quite impressive.
  • Looking at the last year, AERI shows a very strong growth in Revenue. The Revenue has grown by 105.42%.
  • The Revenue has been growing by 100.24% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)94.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)105.42%
Revenue growth 3Y100.24%
Revenue growth 5YN/A
Sales Q2Q%23.25%

3.2 Future

  • Based on estimates for the next years, AERI will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.85% on average per year.
  • Based on estimates for the next years, AERI will show a very strong growth in Revenue. The Revenue will grow by 21.90% on average per year.
EPS Next Y-85.62%
EPS Next 2Y-0.49%
EPS Next 3Y24.72%
EPS Next 5Y12.85%
Revenue Next Year23.8%
Revenue Next 2Y27.33%
Revenue Next 3Y26.9%
Revenue Next 5Y21.9%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AERI Yearly Revenue VS EstimatesAERI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M
AERI Yearly EPS VS EstimatesAERI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AERI. In the last year negative earnings were reported.
  • Also next year AERI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AERI Price Earnings VS Forward Price EarningsAERI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60 -80

4.2 Price Multiples

Industry RankSector Rank
P/FCF 285.78
EV/EBITDA -38.22
AERI Per share dataAERI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • AERI's earnings are expected to grow with 24.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.49%
EPS Next 3Y24.72%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for AERI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AERIE PHARMACEUTICALS INC

NASDAQ:AERI (11/18/2022, 8:21:01 PM)

After market: 15.25 0 (0%)

15.25

+0.01 (+0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-03
Earnings (Next)02-22
Inst Owners4.85%
Inst Owner Change0%
Ins Owners2.91%
Ins Owner Change0%
Market Cap753.62M
Revenue(TTM)213.94M
Net Income(TTM)-36.55M
Analysts71.43
Price Target15.63 (2.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.81%
Min EPS beat(2)39.47%
Max EPS beat(2)44.16%
EPS beat(4)4
Avg EPS beat(4)85.81%
Min EPS beat(4)0.99%
Max EPS beat(4)258.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.22%
Min Revenue beat(2)-0.18%
Max Revenue beat(2)0.62%
Revenue beat(4)2
Avg Revenue beat(4)63.94%
Min Revenue beat(4)-2.07%
Max Revenue beat(4)257.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.52
P/FCF 285.78
P/OCF 105.15
P/B N/A
P/tB N/A
EV/EBITDA -38.22
EPS(TTM)-0.16
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)0.05
FCFY0.35%
OCF(TTM)0.15
OCFY0.95%
SpS4.33
BVpS-3.32
TBVpS-3.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -9.73%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -12.49%
PM (TTM) -17.09%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity -1.91
Debt/FCF 118.54
Debt/EBITDA N/A
Cap/Depr 70.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 1.92
Altman-Z -2.71
F-Score5
WACC8.3%
ROIC/WACCN/A
Cap/Depr(3y)97.96%
Cap/Depr(5y)541.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y-85.62%
EPS Next 2Y-0.49%
EPS Next 3Y24.72%
EPS Next 5Y12.85%
Revenue 1Y (TTM)105.42%
Revenue growth 3Y100.24%
Revenue growth 5YN/A
Sales Q2Q%23.25%
Revenue Next Year23.8%
Revenue Next 2Y27.33%
Revenue Next 3Y26.9%
Revenue Next 5Y21.9%
EBIT growth 1Y80.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.26%
EBIT Next 3Y27.69%
EBIT Next 5Y14.97%
FCF growth 1Y102.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y106.28%
OCF growth 3YN/A
OCF growth 5YN/A

AERIE PHARMACEUTICALS INC / AERI FAQ

What is the fundamental rating for AERI stock?

ChartMill assigns a fundamental rating of 3 / 10 to AERI.


What is the valuation status of AERIE PHARMACEUTICALS INC (AERI) stock?

ChartMill assigns a valuation rating of 0 / 10 to AERIE PHARMACEUTICALS INC (AERI). This can be considered as Overvalued.


Can you provide the profitability details for AERIE PHARMACEUTICALS INC?

AERIE PHARMACEUTICALS INC (AERI) has a profitability rating of 4 / 10.


What is the financial health of AERIE PHARMACEUTICALS INC (AERI) stock?

The financial health rating of AERIE PHARMACEUTICALS INC (AERI) is 2 / 10.